Lineage Cell Therapeutics, Inc. LCTX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Lineage Cell Therapeutics, Inc. reported revenue across 2 products and services; the largest, Collaboration Revenues, was $13.6M, 93.5% of the filed sum (+67.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Collaboration Revenues$13.6M93.5%+67.0% yoy
- Royalties License And Other Revenues$947K6.5%-29.9% yoy
Members sum to the consolidated $14.6M for this period.
- Outside the United States$2.5M100.0%no prior
Members sum to $2.5M against $14.6M consolidated (residual $12.1M) - eliminations or corporate lines the filer did not tag on this axis.
- Collaboration Revenues$1.57M91.3%+24.0% yoy
- Royalties License And Other Revenues$150K8.7%-35.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.